Liposomal amphotericin B: Clinical experience and perspectives

Expert Review of Anti-Infective Therapy

Volumn 3, Issue 2, 2005, Pages 167-181

  Gibbs, Winter J ^a,b   Drew, Richard H ^a,b   Perfect, John R ^b  

^a Campbell University   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antifungal; Liposomal amphotericin B; Polyene

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; CYCLOSPORIN; ECHINOCANDIN; ERGOSTEROL; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; LIPOSOME; MICAFUNGIN; PLACEBO; POSACONAZOLE; RAVUCONAZOLE; SOLUBILIZER; VORICONAZOLE;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLOSIS; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANDIDA ALBICANS; CANDIDIASIS; CHILL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CHOICE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INFUSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERANCE; DYSPNEA; ERADICATION THERAPY; FEBRILE NEUTROPENIA; FLUSHING; FUNGAL COLONIZATION; FUNGAL MENINGITIS; GASTROINTESTINAL SYMPTOM; GROWTH INHIBITION; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; HYPOXIA; IN VITRO STUDY; KIDNEY DYSFUNCTION; LEG PAIN; LIVER TOXICITY; MUCORMYCOSIS; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OPTIMAL DRUG DOSE; PHOTOTOXICITY; REVIEW; RIGOR; SIDE EFFECT; SURVIVAL RATE; THORAX PAIN; URTICARIA; VISCERAL LEISHMANIASIS; VISUAL DISORDER;

EID: 17844382393     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.3.2.167     Document Type: Review

References (127)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348, 1546-1554 (2003).
2. Gudlaugsson O, Gillespie S, Lee K et al. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37, 1172-1177 (2003).
3. NNIS System. National nosocomial infection surveillance (NNIS) system report, data summary from January 1990 to May, issued June 1999. Am. J. Infect. Control 27, 520-532 (1999).
4. Hayes-Lattin B, Maziarz RT. Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders. Leuk. Lymph. 45, 669-680 (2004).
5. Ostrosky-Zeichner L. New approaches to the risk of Candida in the intensive care unit. Curr. Opin. Infect. Dis. 16, 533-537 (2003).
6. Perfect J, Casadevall A. Cryptococcosis. Infect. Dis. Clin. North Am. 16, 837-874 (2002).
7. Denning DW, Marinus A. Cohen J et al. An EORTC multicenter prospective survey of invasive aspergillosis in hematological patients: diagnosis and therapeutic outcome. J. Infect. 37, 173-180 (1998).
8. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12, 308-329 (1990).
9. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new 'gold standard'. Clin. Infect. Dis. 37, 415-425 (2003).
10. Abelcet®, product information. Enzon Pharmaceuticals, Inc. NJ, USA (2002).
11. Amphotec®, product information. Intermune, Inc., CA, USA (2001).
12. AmBisome®, product information. Fujisawa Healthcare, Inc., IL, USA (2000).
13. Dix SP, Andriole VT. Lipid formulations of amphotericin B. Curr. Clin. Top. Infect. Dis. 20, 1-23 (2000).
14. White MH, Bowden RA, Sandler ES et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin. Infect. Dis. 27(2), 296-302 (1998).
15. Bowden RA, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. 35, 359-366 (2002).
16. Moreau P, Milpied N, Fayette N, Ramee JF, Harousseau JL. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J. Antimicrob. Chemother. 30, 535-541 (1992).
17. Calliot D, Reny G, Solary E et al. A controlled trial of the tolerance of amphotericin B infused in dextrose or in intralipid in patients with hematological malignancies. J. Antimicrob. Chemother. 33, 603-613 (1994).
18. Pascual B, Ayestaran A, Montoro J et al. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia. Ann. Pharmacother. 29, 1197-1201 (1995).
19. Petit N, Parola P, Dhiver C, Gastaut JA. Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients. J. Antimicrob. Chemother. 38, 154-157 (1996).
20. Pappas P, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38, 161-189 (2004).
21. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Clin. Infect. Dis. 30, 710-718 (2000).
22. Espinel-Ingroff A, Pfaller M, Messer S et al. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J. Antimicrob. Chemother. 42, 718-721 (2004).
23. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12, 40-79 (1999).
24. Sporanox® oral solution/injection, product information. Janssen Pharma, NJ, USA (2004).
25. Sporanox® capsules, product information. Janssen Pharma, NJ, USA (2002).
26. Herbrect R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347, 408-415 (2002).
27. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36, 198-202 (1998).
28. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal. amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. 346, 225-234 (2002).
29. Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev. Anti Infect. Ther. 2(4), 485-497 (2004).
30. Voriconazole®, product information. Pfizer, Inc., NY, USA (2004).
31. Dannaoui E, Meletiadis J, Mouton JW, Meis J, Verweij P. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother. 51, 45-52 (2003).
32. Cancidas®, product information. Merck & Co., Inc., NJ, USA (2004).
33. Raasch RH. Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev. Anti Infect. Ther. 2(4), 499-508 (2004).
34. Higashiyama Y, Kohno S. Micafungin: a therapeutic review. Expert Rev. Anti Infect. Ther. 2(3), 345-355 (2004).
35. Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and preclinical experience. J. Antimicrob. Chemother. 49, 21-30 (2002).
36. Adler-Moore J. AmBisome targeting to fungal infections. Bone Marrow Transplant. 14(Suppl. 5), S3-S7 (1994).
37. Ellis D. Amphotericin B: spectrum and resistance. J. Antimicrob. Chemother. 49 (Suppl. S1), 7-10 (2002).
38. Francis P, Lee JW, Hoffman A et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J. Infect. Dis. 169, 356-368 (1994).
39. Adler-Moore J, Chiang S, Satorius A et al. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J. Antimicrob. Chemother. 28(Suppl. B), 63-71 (1991).
40. Clemons KV, Stevens DA. Comparison of a liposomal amphotericin B formulation (AmBisome) and deoxycholate amphotericin (Fungizone) for the treatment of paracoccidiodomycosis. J. Med. Vet. Mycol. 31, 387-394 (1993).
41. Clemons KV, Stevens DA. Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis. J. Antimicrob. Chemother. 32, 465-472 (1993).
42. Clemons KV, Stevens DA. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis. J. Antimicrob. Chemother. 30, 353-363 (1992).
43. Clark JM, Whitney RR, Olsen SJ et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob. Agents Chemother. 35, 615-621 (1991).
44. Hostetler JS, Clemons KV, Hanson LH, Stevens DA. Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis. Antimicrob. Agents Chemother. 36, 2656-2660 (1992).
45. Clemons KV, Stevens DA. Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob. Agents Chemother. 35, 1829-1833 (1991).
46. Bekersky I, Fielding RM, Dressler DE et al. Pharmacokinetics, excretion, and mass balance of 14C after administration of 14C-cholesterol-labeled AmBisome to healthy volunteers. J. Clin. Pharmacol. 41, 963-971 (2001).
47. Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJ. Liposomal and lipid formulations of amphotericin B. Clin. Pharmacokinet. 23, 279-291 (1992).
48. Heinemann V, Bosse D, Jehn U et al. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients. Antimicrob. Agents Chemother. 41, 1275-1280 (1997).
49. Eldem T, Arican-Cellat N, Agabeyoglu I, Akova M, Kansu E. Pharmacokinetics of liposomal amphotericin B in neutropenic cancer patients. Int. J. Pharm. 213, 153-161 (2001).
50. Bekersky I, Fielding RM, Dressler DE et al. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agents Chemother. 46, 834-840 (2002).
51. Tollemar J, Ringden O, Tyden G. Liposomal amphotericin B (AmBisome) treatment in solid organ and bone marrow transplant recipients: efficacy and safety evaluation. Clin. Transplant. 4, 167-176 (1990).
52. Boswell GW, Buell D, Bekersky I. AmBisome (liposomal amphotericin B): a comparative review. J. Clin. Pharmacol. 38, 583-592 (1998).
53. Walsh TJ, Goodman JL, Pappas P et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus spp. and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 45, 3487-3496 (2001).
54. Bekersky I, Fielding RM, Dressler DE et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. 46, 828-833 (2002).
55. Gubbins PO, McConnell SA, Amsden JR, Anaissie E. Comparison of liposomal amphotericin B plasma and tissue concentrations following a single large (15 mg/kg) dose or daily 1 mg/kg dosing. Proceedings of the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. 30 October-2 November 2004 (Abstract A-33).
56. Adler-Moore J, Proffitt RT. Development, characterization, efficacy, and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J. Liposome Res. 3, 429-450 (1993).
57. Groll AH, Giri H, Petraitis V et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis. 182, 274-282 (2000).
58. AmBisome®, product characteristics. Gilead Sciences International Ltd, CA, USA (2004).
59. Heinemann V, Bosse D, Jehn U et al. Enhanced pulmonary accumulation of liposomal amphotericin B (AmBisome) in acute liver transplant failure. J. Antimicrob. Chemother. 40, 295-297 (1997).
60. Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41, 1392-1395 (1997).
61. Lewis RE, Lund BC, Klepser ME, Ernst EL. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob. Agents Chemother. 42, 1382-1386 (1998).
62. Di Bonaventura G, Spedicato I, Picciani C, D'Antonio D, Piccolomini R. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Antimicrob. Agents Chemother. 48, 4453-4456 (2004).
63. Dodds ES, Drew RH, Perfect JR. Antifungal pharmacodynamics: review of the literature and clinical applications. Pharmacotherapy 20, 1335-1355 (2000).
64. Mattiuzzi GN, Estey E, Raad I et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 97, 450-456 (2003).
65. Kelsey SM, Goldman JM, McCann S et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant. 23, 163-168 (1999).
66. Biancofiore G, Bindi ML, Baldassarri R et al. Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study. Transplant. Int. 15, 341-347 (2002).
67. Bennett JE, Powers JH, Walsh TJ et al. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin. Infect. Dis. 36(Suppl. 3), S117-S122 (2003).
68. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N. Engl, J. Med. 340, 764-771 (1999).
69. Walsh TJ, Teppler H, Donowitz G et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351, 1391-1402 (2004).
70. Fleming RV, Kantarjian HM, Husni R et al. Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk. Lymph. 40, 511-520 (2001).
71. Juster-Reicher A, Leibovitz; E, Linder N et al. Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low-birth-weight infants. Infection 28, 223-226 (2000).
72. Juster-Reicher A, Flidel-Rimon O, Amitay M et al. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur. J. Clin. Microbiol. Infect. Dis. 22, 603-607 (2003).
73. Ringden O, Meunier F, Tollemar J et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J. Antimicrob. Chemother. 28(Suppl. B), 73-82 (1991).
74. Ruiz I, Olive T, Gavalda J et al. High doses of AmBisome in the treatment of invasive aspergillosis. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy 14-17 September 2003 (Abstract M-966).
75. van der Horst CM, Saag MS, Cloud G et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N. Engl. J. Med. 337, 15-21 (1997).
76. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob. Agents Chemother. 48, 693-715 (2004).
77. Coker RJ, Viviani M, Gazzard BG et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS 7, 829-835 (1993).
78. Viviani M, Rizzardini G, Tortorano AM et al. Lipid-based amphotericin B in the treatment of cryptococcosis. Infection 22, 137-142 (1994).
79. Leenders AC, Reiss P, Portegies P et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 11, 1463-1471 (1997).
80. Hamill R. Sobel JD, El-Sadr W et al. Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. 26-29 September 1999 (Abstract 1161).
81. Clemons KV, Stevens DA. Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob. Agents Chemother. 42, 899-902 (1998).
82. Johnson PC, Wheat LJ, Cloud GA et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann. Intern. Med. 137, 105-109 (2002).
83. Seaman J, Boer C, Wilkinson R et al. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin. Infect. Dis. 21, 188-193 (1995).
84. Thakur CP, Pandey AK, Sinha GP et al. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans. R. Soc. Trop. Med. Hyg. 90, 319-322 (1996).
85. Davidson RN, di Martino L, Gradoni L et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin. Infect. Dis. 22, 938-943 (1996).
86. di Martino L, Davidson RN, Giacchino R et al. Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J. Pediatr. 131, 271-277 (1997).
87. Berman JD, Badaro R. Thakur CP et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull. World Health Organ. 76, 25-32 (1998).
88. Thakur CP. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. Int. J. Antimicrob. Agents. 17, 67-70 (2001).
89. Sundar S, Jha TK, Thakur CP et al. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am. J. Trop. Med. Hyg. 66, 143-146 (2002).
90. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. Br. Med. J. 323, 419-422 (2001).
91. Sundar S, Jha TK, Thakur CP et al. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin. Infect. Dis. 37, 800-804 (2003).
92. Chowfin A. Tight R, Mitchell S. Recurrent blastomycosis of the central nervous system: case report and review. Clin. Infect. Dis. 969-971 (2000).
93. Antony S, Dominguez DC, Sotelo E. Use of liposomal amphotericin B in the treatment of disseminated coccidioidomycosis. J. Natl. Med. Assoc. 95, 982-985 (2003).
94. Wang J, Hung C, Chang S, Chueh S, La M. Disseminated Penicillum marneffei infection in a renal-transplant recipient successffully treated with liposomal amphotericin B. Transplantation 76, 1136-1137 (2003).
95. Aliff TB, Maslak PG, Jurcic JG et al. Refractory aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and lipsomal amphotericin. Cancer 97, 1025-1032 (2003).
96. Byun R, Siddiqui J, McNeil A, Cohen S. Regression of central nervous system (CNS) aspergillus lesion with combination liposomal amphotericin B and caspofungin in a patient with human immunodeficiency syndrome (HIV) infection. Proceedings of the 40th Meeting of the Infectious Diseases Society of America. 24-27 October 2002 (Abstract 357).
97. Nguyen HH, Avante CJ, Siddiqui J, King J, Cohen SH. Successful treatment of candidemia with caspofungin and liposomal amphotericin B after failure of monotherapy. Proceeedings of the 13th Focus on Fungal Infections Meeting. 19-21 March 2003 (Abstract 40).
98. Clemons KV, Espiritu M, Parmar P. Stevens DA. Combination therapy studies using AmBisome, amphotericin B deoxycholate, caspofungin, micafungin, and voriconazole against CNS aspergillosis. Proceedings of the 44th Interscience Conference an Antimicrobial Agents and Chemotherapy 30 October-2 November 2004 (Abstract M-1140).
99. Ghannoum M, Long L, Yearick D, Isham N. The effect of sequential treatment with AmBisome and voriconazole on the inhibition of Aspergillus fumigatus. Proceedings of the 40th Meeting of the Infectious Diseases Society of America. 24-27 October 2002 (Abstract 356).
100. Kontoyiannis D, Boktour M, Hanna H, Hachem RY, Raad I. Does itraconazole (ITRA) added to amphotericin B or its lipid formulation (AMB/LPD) improve outcome of primary treatment of invasive aspergillosis (IA)? Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. 30 October-2 November 2004 (Abstract M-1032).
101. Meletiadis J, Petraitis V, Petraitiene R et al. Antagonistic interaction between liposomal amphotericin B and ravuconazole in experimental invasive pulmonary aspergillosis: implications for combination therapy. Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. 30 Ocotber-2 November 2004 (Abstract M-238).
102. Klepser ME. Amphotericin B in lung transplant recipients. Ann. Pharmacother. 36, 167-169 (2002).
103. Calvo V, Borro J, Morales P et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Chest 115, 1301-1304 (1999).
104. Reichenspurner H, Gamberg P, Nitschke M et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant. Proc. 29, 627-628 (1997).
105. Monforte V, Roman A, Gavalda J et al. Nebulized amphotericin B prophylaxis for aspergillus infection in lung transplantation: study of risk factors. J. Heart Lung Transplant. 20, 1274-1281 (2001).
106. Dubois J, Bartter T, Gryn J, Pratter M. The physiologic effects of inhaled amphotericin B. Chest 108, 750-753 (1995).
107. Erjavec Z, Woolthuis G, Bries-Hospers H. Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur. J. Clin. Microbiol. Infect. Dis. 16, 364-368 (1997).
108. Monforte V, Gavalda J, Roman A et al. Pharmacokinetics and efficacy of nebulized AmBisome in lung transplantation. Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. 30 Ocotber-2 November 2004 (Abstract M-1042).
109. Roden MM, Nelson LD, Knudsen TA et al. Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. Clin. Infect. Dis. 36, 1213-1220 (2003).
110. Johnson MD, Drew RH, Perfect JR. Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. Pharmacotherapy 18, 1053-1061 (1998).
111. Wingard J, White M, Anaissie E et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin. Infect. Dis. 31, 1155-1163 (2000).
112. Deray G. Amphotericin B nephrotoxicity, J. Antimicrob. Chemother. 49(Suppl. 1), 37-41 (2002).
113. Bates DW, Su L, Yu DT et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int. 60, 1452-1459 (2001).
114. Luber AD, Maa L, Lam M, Guglielmo BJ. Risk factors for amphotericin B-induced nephrotoxicity. J. Antimicrob. Chemother. 43, 267-271 (1999).
115. Fisher MA, Talbot GH, Maislin G et al. Risk factors associated with amphotericin B-associated nephrotoxicity. Ant. J. Med. 87, 547-552 (1989).
116. Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin. Infect. Dis. 32, 686-693 (2001).
117. Ellis M, Spence D, de Pauw B et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin. Infect. Dis. 27, 1406-1412 (1998).
118. Mayer J, Doubek M, Doubek J et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J. Infect. Dis. 186, 379-388 (2002).
119. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 h: randomised controlled trial. Br. Med. J. 322, 579-584 (2001).
120. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin. Infect. Dis. 36, 943-951 (2003).
121. Ringden O, Andstrom E, Remberger M, Svahn B-M, Tollemar J. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant. 14(Suppl. 5), S10-S14 (1994).
122. Drug Topics Red Book. Fleming T (Ed.). Thomson Healthcare PDR, NJ, USA (2004).
123. Cagnoni PJ, Walsh TJ, Prendergast MM et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J. Clin. Oncol. 18, 2476-2483 (2000).
124. Kuti JL, Kotapati S, Williams P et al. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics 22, 301-310 (2004).
125. Greenberg RN, Cagnoni PJ, Wingard JR, Prendergast NW, Tong KB. Factors associated with increased hospital costs in patients treated with lipid based amphotericin B for empirical therapy. J. Med. Econ. 5, 109-118 (2002).
126. Wingard J, Leather HL, Walsh TJ et al. Pharmacoeconomic analysis comparing caspofungin to liposomal amphotericin B for empirical therapy persistently febrile neutropenic patients. Proceedings of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. 30 Ocotber-2 November 2004 (Abstract 0-1619).
127. Mazzola JL, Belliveau PP, Cheeseman SH. Guidelines for liposomal amphotericin B. Am. J. Health. Syst. Pharm. 60, 1480-1481 (2003).